Aegis Capital Starts Trevi Therapeutics (TRVI) at Buy

March 29, 2022 9:34 AM EDT
Get Alerts TRVI Hot Sheet
Price: $1.75 -9.33%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 6 | Down: 13 | New: 58
Join SI Premium – FREE

Aegis Capital analyst Nathan Weinstein initiates coverage on Trevi Therapeutics (NASDAQ: TRVI) with a Buy rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Trevi Therapeutics click here. For more ratings news on Trevi Therapeutics click here.

Shares of Trevi Therapeutics closed at $2.16 yesterday.

You May Also Be Interested In

Related Categories

Hot New Coverage, New Coverage